ANTI-OSTEOPOROSIS AND FRACTURE HEALING MARKET ANALYSIS
In the recent past, various regulatory bodies such as European Medicines Agency (EMA), U.S. Food and Drug Administration (FDA), Medicines and Healthcare Products Regulatory Agency (MHRA), and others approved new drugs for treatment of osteoporosis. Approval and launch of such new drugs are expected to drive global Anti-Osteoporosis and Fracture Healing Market growth over the forecast period. For instance, in April 2017, Radius Health Inc., a biopharmaceutical company, received approval from U.S. Food and Drug Administration (FDA) for TYMLOS (abaloparatide) injection, for treating postmenopausal women with osteoporosis who are at high risk of fracture. This drug reduces the occurrence of spinal cord and peripheral skeleton fractures in postmenopausal women.
Furthermore, key players are launching new treatment methods for osteoporosis in the market. For instance, in January 2016 Ahn-Gook Pharmaceutical Co., Ltd., a South Korea based pharmaceutical company, received approval from the Korean Ministry of Food and Drug Safety (MFDS) for marketing of Binosto buffered alendronate in Korea. Alendronate reduces bone loss and buffering reduces the exposure of stomach and esophagus to acidified alendronate. Such new product launches are expected to fuel global Anti-Osteoporosis and Fracture Healing Market growth over the forecast period.
Anti-Osteoporosis and Fracture Healing Market Taxonomy
The global Anti-Osteoporosis and Fracture Healing Market is segmented on the basis of drug class, route of administration, distribution channel, and regions.
By Drug Class
By Route of Administration
By Distribution Channel
By Region
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 